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Research
AbstrACt
background The National Institute for Health and Care 
Excellence (NICE) was established in 1999 and provides 
national guidance and advice to improve health and 
social care. Several steps in the research cycle have been 
identified that can support the reduction of waste that 
occurs in biomedical research. The first step in the process 
is ensuring appropriate research priority setting occurs 
so only the questions that are needed to fill existing gaps 
in the evidence are funded. This paper summarises the 
research priority setting processes at NICE.
Methods NICE uses its guidance production processes 
to identify and prioritise research questions through 
systematic reviews, economic analyses and stakeholder 
consultations and then highlights those priorities by 
engagement with the research community. NICE also 
highlights its methodological areas for research to ensure 
the appropriate development and growth of the evidence 
landscape.
results NICE has prioritised research questions through 
its guidance production and methodological work and has 
successfully had several research products funded through 
the National Institute for Health Research and Medical 
Research Council. This paper summarises those activities 
and results.
Conclusions This activity of NICE therefore reduces 
research waste by ensuring that the research it 
recommends has been systematically prioritised through 
evidence reviews and stakeholder input.
IntroduCtIon
There is no doubt that the substantial public 
and private investment in biomedical research 
(estimated to be around US$240 billion in 
2010)1 has led to significant improvements 
to the quality of life of people. However, not 
all research yields such benefits, and though 
some waste is unavoidable due to the nature 
of science, many improvements to the way we 
conduct our work can be made to ensure that 
our investments are sound and the value of 
our research is increased.1 2 Getting the first 
step of the research cycle, that is, appropriate 
priority setting of research or identifying the 
correct research question to fund, is key to 
this being successful.1 
Previous research has shown that there is a 
huge mismatch between the research that is 
funded and the research needed by the end 
users. A study found that only 9 out of 334 
research articles highlighted priorities rele-
vant to patients or clinicians.2 A second study 
found that while the majority of trials funded 
were related to drugs, the end users were 
much more interested (80%) in research 
about ‘education and training, service delivery, 
psychological interventions, physical interventions, 
exercise, complementary interventions, diet etc’, 
compared with research in drugs (20%).1
Another problem noted is that often the 
new research ignores what is already known 
about the problem and does not take into 
account previous research and therefore 
can duplicate information and give little 
additional value.1 2 Moreover, such research 
may miss the true knowledge gaps that need 
answering, and this can often be compounded 
by the failure to publish negative research 
(publication bias) that can go undetected 
unless methodology such as funnel plots are 
used. Even if an appropriate research gap is 
identified, inappropriate design or statistical 
strengths and limitations of this study
 ► Highlights the importance of reducing research 
waste and the prioritisation of research as a key step 
in that process.
 ► Describes the systematic prioritisation of research 
done by National Institute for Health and Care 
Excellence (NICE).
 ► Illustrates the methodological research undertaken 
from prioritised topics by NICE in recent years.
 ► This paper is limited to the prioritisation of research 
undertaken at NICE and it does not reflect all the 
work the nstitute does to reduce research waste.
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analyses or the problem of ‘effect to bias ratio’ (where the 
magnitude of the effect size and biases like selection or 
confounding, are similar) may mean that the validity of 
any results may be questionable.3 4
The National Institute for Health and Care Excellence 
(NICE) is an independent organisation responsible for 
providing evidence-informed guidance on health and 
social care for England.5 6 NICE guidelines (clinical, 
public health and social care), quality standards, Health 
Technology Assessments (HTA) and other products 
help to deliver the best possible care within the limited 
resources available.5 6 The Science Policy and Research 
(SP&R) programme7 works together with various 
academic, charity and research funding organisations to 
enable the appropriate research to be done. It is now also 
working with life sciences companies, using European 
Commission funding through the Innovative Medicines 
Initiative (IMI) to take this work forward. In this paper, 
we summarise these processes and the work that has been 
undertaken through these mechanisms.
research priorities identified through systematic reviews 
(guideline or HtA production)
NICE guidance is based on the synthesis of evidence 
primarily through the process of systematic reviewing 
and, if appropriate, health economic modelling and 
cost-effectiveness decision analysis that are presented 
using Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) profiles that allow for 
a transparent representation of the confidence in the 
evidence available for decision making.8 The results of 
this work are discussed by independent advisory commit-
tees (consisting of members external to NICE), which can 
include a diversity of National Health Service staff, health-
care professionals, social care practitioners, commis-
sioners and providers of care, patients, service users and 
carers, industry and academics. The committees, through 
a process of guided deliberation of the evidence, reach 
conclusions by formally making draft recommenda-
tions. During a period of public consultation, external 
stakeholders can comment on draft recommendations 
before they are finalised and eventually published.9 The 
evidence base supporting guidance recommendations 
are reviewed every few years to ensure that any results 
potentially demonstrating a change in practice or care 
are formally considered for updating recommendations.
This process explicitly describes the evidence base and 
identifies where there are gaps, uncertainties or conflicts, 
in the existing evidence. Many uncertainties identified 
may be interesting to answer but could have little impact 
on people’s care or NICE’s ability to make appropriate 
evidence-based and evidence-informed recommenda-
tions. Uncertainties can arise because there is no evidence 
available or due to the absence of relevant research or if 
research has been done but not yet published. Or there 
may be evidence available but there is still insufficient 
information on which to base a recommendation (eg, due 
to inadequate reporting or poor quality), or the research 
is out of date (eg, a systematic review that needs updating 
with recent trials or if clinical practice has changed). 
However, if these uncertainties could have an impact, and 
support future NICE guidance recommendations, it is 
important for the institute to make recommendations for 
research (see table 1).
These recommendations are deliberated, discussed, 
agreed and formulated by the independent advisory 
committees and the external community (both specialist 
and public) that are then invited to comment and 
contribute.9 The final recommendations are identifiable 
in the guidance and are also collated into the publicly 
available NICE research recommendations database.10 
NICE then liaises with the research community to ensure 
they are addressed as detailed in the paragraphs that 
follow. By making research recommendations, NICE 
is looking to steer the research community for them to 
generate new evidence to inform the future guidance 
update and review cycle. If gaps remain in the evidence 
base after several years, the committee may consider 
keeping, removing or archiving the research recommen-
dations based on any new findings. In 2010 (updated 
in 2015), NICE established a formal guide to support 
this process and to provide a route to ensuring they are 
picked up as key topics for research funding.11 The guide 
describes a step-by-step approach to identifying uncer-
tainties, formulating research recommendations and 
research questions, prioritising them and communicating 
them to researchers and research funders (see figure 1).
NICE works closely with National Institute for Health 
Research (NIHR; a government body that supports health 
and care research of national research priorities)12 to 
prioritise, promote and commission its research recom-
mendations. The identified topics are considered by a 
number of their different research programmes, partic-
ularly the HTA, Public Health Research and the Health 
Services & Delivery Research programmes. If they are 
found to be suitable and fulfil their criteria, they enter 
the commissioning process. This process has evolved over 
the last 10 years and since 2005, over £59 million worth of 
these research projects have been funded (see table 2). 
In 2015, NICE and NIHR Evaluation, Trials and Studies 
Coordinating Centre (NETSCC) agreed a fast-tracked 
route for the most important research recommendations, 
to be flagged under the ‘NICE Key Priority’ designation. 
These research recommendations have the potential to 
have the highest impact on future guidance recommen-
dations and people’s care.
Methodological research priorities: ‘research on research’
The Edinburgh Reducing Waste conference in 2015 
highlighted the importance of being efficient in the 
‘what’ but also the ‘how’ research is done. While the basic 
methodology of systematic reviews and cost-effectiveness 
analyses may be well established, there is still contro-
versy about ‘best practice’ and challenges frequently 
arise in the context of specific technologies, particularly 
when decisions are negative. It is therefore vital that 
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methodological research is undertaken. Inadequacies in 
the evidence base have required the exploration of newer 
methods such as indirect comparisons and the use of 
network meta-analyses that allow for comparisons across 
different drugs and interventions where those trials have 
not been undertaken.13 Different perspectives exist about 
what data constitute as evidence and about what should 
be used for decision making. Due to the paucity of the 
evidence base for some interventions, particularly in the 
public health and social care domains, NICE has always 
considered the ‘best available’ evidence to inform its deci-
sions, which move beyond randomised controlled trials, 
using GRADE to determine the validity of the collective 
evidence.8 9 13 In order to ensure that the evidence NICE 
receives is fit for decision making, each of NICE’s guid-
ance programmes have a methods guide that are regu-
larly updated to incorporate new developments. NICE 
Scientific Advice works directly with commercial evidence 
producers on a fee-for-service basis to ensure the appro-
priate evidence is available for decision making.
In 2008, NICE had its first comprehensive review of 
the methodological research needed for future devel-
opment of the work of the institute (methodological 
priorities for research), funded by the Medical Research 
Council (MRC) and NIHR joint Methodology Research 
Programme (MRP).14 The methodological review identi-
fied and prioritised methods research topics through a 
focused literature review, interviews, an email survey, a 
workshop and web-based feedback exercise. Participants 
were members of the NICE secretariat and its advisory 
bodies, representatives from academia, industry and 
other organisations working closely with NICE. The first 
prioritised project the MRP funded in 2008 was on the 
appropriate use of ‘only in research’ decision15 and a 
further nine projects were funded through another MRP 
call via their needs-led route in 2009 (over £2.3 million, 
see table 3).
To ensure that NICE had robust processes for timely 
identification, prioritisation and communication of 
methodological research needs, an Internal Research 
Table 1 Example format for research recommendation rationale to support prioritisation
Potential criterion Explanation
Importance to patients, service users or the 
population
What would be the impact of any new or altered guidance on the population 
(eg, acceptability to patients or service users, quality of life, morbidity or 
disease prevalence, severity of disease or mortality)?
Relevance to NICE guidance How would the answer to this question change future NICE guidance (ie, 
generate new knowledge or evidence)? How important is the question to the 
overall guidance?
 ► High: the research is essential to inform future updates of key 
recommendations in the guidance.
 ►Medium: the research is relevant to the recommendations in the guidance, 
but the research recommendations are not essential to future updates.
 ► Low: the research is of interest and will fill existing evidence gaps.
Relevance to the NHS, public health, social 
care and voluntary sectors
What would be the impact on the NHS, public health, social care and voluntary 
sector and (if relevant) the public sector of any new or altered guidance (eg, 
financial advantage, or effect on staff, strategic planning or service delivery)?
National priorities Is the question relevant to a national priority area (such as a national policy or 
parliamentary paper)?
If so, specify the document.
Current evidence base What are the problems with the current evidence base? (That is, why is further 
research needed?)
Is there any relevant ongoing research that may resolve the uncertainty?
Equality Does the research recommendation have any relevance to equality? For 
example, does it focus on groups needing special consideration, or on a 
technology, intervention or service that is not available for use by people with 
certain disabilities?
What is known about the impact of the intervention on the health gradient?
Feasibility Can the proposed research be carried out within a realistic timescale?
Would the sample size needed to resolve the question be feasible?
Would the expense needed to resolve the question be warranted?
Are there any ethical or technical issues?
Other comments Any other important issues that should be mentioned, such as potential 
funders, outcomes of previous attempts to address this issue or 
methodological problems.
NHS, National Health Service; NICE, National Institute for Health and Care Excellence.
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Advisory Group (IRAG; formerly the internal methods 
advisory group) was established in 2010. This group was 
tasked to develop the institute’s methodological devel-
opment needs in both the short term and long term by 
continuing the systematic identification and prioritisation 
of key research uncertainties on an ongoing basis and 
working with MRP to commission research.12 The group 
consisted of representatives of the different guidance 
and non-guidance producing centres and programmes 
across NICE, who were supported as and when needed 
by external research advisors from academia who were 
methodological experts in the fields relevant to the 
work of NICE. Each programme provided their meth-
odological research priorities, and 45 uncertainties were 
collated from across the Institute. These were clarified 
and reprioritised into themes that included modelling 
service delivery, using qualitative evidence to capture 
patients experience, extrapolating data for comorbid and 
paediatric populations and using observational data from 
large datasets for decision making. These were then high-
lighted by MRC through a NICE-specific funding call (see 
figure 2).
Some of the prioritised topics did not receive any bids 
and other internal support mechanisms were used to 
fund them as small scoping projects. This led to more 
clarified research questions, of which one was under-
taken internally by the SP&R programme at NICE on the 
use of colloquial evidence13 and the other to support the 
use of observational data in healthcare decision making 
was put forward as a highlight notice by the MRP in 
2017.16 They also funded two more NICE priorities on 
developing a reference protocol for expert elicitation in 
Figure 1 The NICE research recommendations process. NETSCC, NIHR Evaluation, Trials and Studies Coordinating Centre; 
NICE, National Institute for Health and Care Excellence; NIHR, National Institute for Health Research.
Table 2 Summary of the cost of National Institute of Health Research (NIHR)-funded projects (as of 31 March 2016)
NICE priority topics NICE database topics Total
No of NETS 
projects Funded cost (£)
No of NETS 
projects Funded cost (£)
No of NETS 
projects Funded cost (£)
HTA programme 24 £24 369 414 22 (I TAR) £15 805 225 46 £40 174 639
PHR programme 4 £1 764 186 26 £16 448 522 30 £18 212 708
HS&DR 
programme
NA NA 2 £738 188 2 £738 188
Total 28 £26 133 600 50 £32 991 935 78 £59 125 535
Source: NIHR Evaluations, Trials and Studies (NETS) Coordinating Centre (NETSCC).
HS&DR, Health Services & Delivery Research; HTA, Health Technology Assessment; NA, not applicable; NICE, National Institute for Health 
and Care Excellence; PHR, Public Health Research.
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healthcare decision making in 201617 and going beyond 
health-related quality of life towards a broader quality-ad-
justed life-years measure for use across sectors in 2017.18
The SP&R programme has also participated in a 
project considering the role of social values in priority 
setting as part of an international collaboration to try 
and unpick how cultural contexts of well-being interacted 
with healthcare decision making.19 20 Additionally, the 
programme supported the establishment of a Research 
Support Unit in 2013 to undertake short projects identi-
fied through internal prioritisation by IRAG on method-
ological areas that included reviewing the literature on 
social value judgements relevant for NICE and identifying 
and appraising promising sources of UK clinical, public 
health and social care real-world data.21 Other arrange-
ments for NICE to access research commissioning include 
the Decision Support Unit, the Technical Support Unit 
and the External Assessment Centres that facilitate meth-
odological research for HTAs, clinical guidelines and 
medical technologies evaluation work, respectively. NICE 
has also recently partnered with Myeloma UK to explore 
how patient preferences could be captured and included 
in HTAs more readily.
NICE has also been looking at internationally important 
and relevant research priorities that will potentially have 
a global impact on health and care decision making. It 
has been successful in gaining international cooperation 
and European Commission funding through the IMI 
for some of the key priorities currently facing the field. 
These include the use of real-world data for early deci-
sion making (GetReal),22 the medicines adaptive path-
ways to patients activities to foster access to beneficial 
treatments for the right patient groups at the earliest 
appropriate time in the product life-span in a sustain-
able fashion (ADAPT-SMART)23 and using big data for 
obtaining better outcomes for patients (BD4BO).24 
The Institute has also been actively involved with 
other European Commission funded projects such as 
EUnetHTA (an effective and sustainable network for 
HTA across Europe)25 and DECIDE (patient and public 
focused strategies for communicating evidence-based 
recommendations).26
In 2017 NICE published nine areas that it had, through 
the SP&R programme and the IRAG, identified as prior-
ities for methodological research. These are: (1) real-
world evidence; (2) data science; (3) adaptive pathways; 
(4) patient preferences; (5) improvements in cross-sector 
comparisons; (6) expert elicitation; (7) complex data 
visualisation; (8) precision medicine; and (9) implemen-
tation of NICE guidance. Methodological research in 
these areas will help NICE assess the need for improve-
ment in the methods and processes it uses to produce 
guidance and anticipate and adapt to policy develop-
ments and changes in health and social care delivery in 
Table 3 Methodological research projects funded through Methodology Research Programme (MRP) in 2009 (approximately 
£2.3 million)
Research project
Principal 
investigator
Primary research 
institute
Project 
duration 
(months)
Value 
funded
Widening the spectrum of health outcomes used 
in Health Technology Assessment: integrated 
synthesis and mapping to QALYs
Professor A E Ades University of Bristol 24 238 868
Use of generic and condition-specific measures 
in NICE decision making
Dr L Longworth University of Sheffield 24 289 189
Preparatory study for the re-evaluation of the EQ-
5D tariff
Dr A Tsuchiya University of Sheffield 18 242 969
Economic modelling of diagnostic/treatment 
pathways in NICE clinical guidelines
Dr J Lord Brunel University 24 284 471
Properties of statistical methods for indirect 
and mixed treatment comparison – a computer 
simulation evaluation
Dr F Song University of East 
Anglia
12 96 810
Methodological search filter performance: 
assessment to improve efficiency of evidence 
information retrieval.
Ms C Lefebvre NHS R&D Programme 24 95 833
Methods to estimate the NICE cost-effectiveness 
threshold
Professor M Sculpher University of York 24 351 357
Methods for the Indirect estimation of health 
state utilities
Professor C McCabe University of Leeds 24 194 949
Methods for strengthening evaluation and 
implementation: specifying components of 
behaviour change interventions
Professor S Michie University College 
London
36 509 200
EQ-5D, EuroQol 5 dimensions; NICE, National Institute for Health and Care Excellence; QALYs, quality-adjusted life-years.
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the next few years. By only highlighting methodological 
research areas to funders that were systematically prior-
itised, NICE ensures that only questions whose answers 
will impact its future work are studied, therefore doing its 
part to reduce research waste.1
dIsCussIon
Priority setting is an explicit method that considers what 
to fund by weighing the trade-offs between the various 
options in the process.27 It is imperative to avoid research 
waste such that only key gaps in knowledge are fulfilled 
by undertaking new research that help build a more 
complete evidence landscape for future policy develop-
ment and better clinical practice. Systematic approaches 
to research priority setting improve the transparency of 
research management and are often based on a ‘research 
cycle’ approach that includes the identification of research 
questions, ranking their priority, identifying existing 
research, and setting priorities for primary research, and 
involving relevant stakeholders at key points throughout 
the cycle.28 It is therefore essential that a formal process 
of prioritisation of research be established within guid-
ance-producing organisations, with the involvement of all 
legitimate stakeholders, to increase the ownership of the 
Figure 2 Process of identifying methodological research priorities at NICE and relationship with Medical Research Council 
(MRC): example 2010–2012. NICE, National Institute for Health and Care Excellence.
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ensuing research and the likelihood of the results influ-
encing practice and policy.29
Creating research recommendations is part of the guid-
ance production cycle, and they should:
 ► identify any uncertainties that may affect people’s care
 ► be developed using an appropriate technique to frame 
research question development, for example popula-
tion, intervention, comparator and outcome (PICO) 
or evidence, population, intervention, comparator, 
outcome and time (EPICOT).
 ► go through a process of stakeholder consultation and 
be reviewed as part of the guidance review and update 
cycle.
This is the path that NICE has taken and therefore has 
a strong emphasis on reducing research waste. The NICE 
research recommendations are derived from the uncer-
tainties identified through the NICE guidance develop-
ment process and are an integral part of the guidance 
development and review cycles. The institute therefore 
reduces research waste by supporting the redirection 
of resources to more valuable activities.30 By making its 
research priorities and funded research publicly avail-
able, it minimises the duplication of research. It also 
drafts research questions with appropriate detail (eg, 
type of study design and sample size required), such that 
the answers obtained from its commissioned research 
are meaningful. Publicly funded guidance development 
bodies have a responsibility to ensure that they are guiding 
appropriate future research based on identified need and 
gaps in the evidence base. This is also true for research 
funders, who also have the same responsibility. NIHR has 
shown that only 5 (11%) of the 47 trials funded over the 
2-year period (2006–2008) were not based on identified 
gaps from systematic reviews, and they had valid reasons 
for doing so.31
Methodological uncertainties derived from NICE also 
go through a process of systematic identification and 
prioritisation and are promoted to funders to encourage 
research being funded into the various aspects of how to 
undertake the development of future guidance. Though 
this paper is limited to describing the prioritisation of 
research undertaken at NICE, we feel it is an important 
part of the role of any HTA or guideline-producing agency 
globally to undertake in order to reduce research waste.
In recent years, NICE has entered into a few inter-
national research collaborations. These are becoming 
increasingly important as sources of research funding, 
particularly within the current economic climate, are 
dwindling. Such partnerships support the identification 
and prioritisation of cross-cutting research needs and also 
potential joint funding routes. There should therefore 
be a shared responsibility between research partners to 
ensure that key research is undertaken and cooperation 
to allow sharing of information to avoid duplication and 
improve efficiency. NICE has partnered with The National 
Center for Biotechnology Information so that there will 
be a PubMed bookshelf dedicated to methods research, 
and the methodological research reports undertaken by 
organisations like NICE would also be indexed and acces-
sible in the future.
A number of methods to identify priority areas for 
research have emerged. These include measuring the 
burden of disease or the expected return from research 
as well as estimates of the welfare losses resulting from 
variations in clinical practice.32 The value of information 
analysis is a more novel approach to prioritising research 
uncertainties that quantifies the expected net benefit 
from the results of the additional research to society, 
against the cost of conducting that piece of research and 
its implementation. Through this framework, the value of 
acquiring additional information to inform the decision 
problem helps alleviate some of the uncertainty had less 
definitive evidence been used instead.33 34 This method 
has a firm foundation in statistical decision theory and 
has been successfully used in other areas of research.32 It 
has also been employed for developing research recom-
mendations from a number of NICE guidance but not yet 
been undertaken routinely.
Other successful initiatives to identify, prioritise and 
promote research uncertainties include the James 
Lind Alliance (now part of NIHR and carried out via 
NETSCC) Priority Setting Partnerships (PSPs). These 
PSPs bring together patients, carers and clinicians using 
transparent methods to prioritise ‘known unknowns’ 
that have been elicited primarily from evidence-based 
knowledge.35 Until January 2016, these research priori-
ties were collated and published in the UK Database of 
Uncertainties about the Effects of Treatments. This was 
launched in 2006 to collate uncertainties from reports 
of systematic reviews and clinical guidelines, protocols 
for systematic reviews (such as those published in the 
Cochrane Database of Systematic Reviews) or from regis-
tered information about ongoing clinical trials. Some of 
the treatment uncertainties came directly from patients 
or carers or from clinicians and cover a wide variety of 
health problems, for example, cancer, mental health 
and skin disorders.35 Another good example can be seen 
from the field of international development where the 
use of evidence gap maps have been developed by the 
International Initiative for Impact Evaluation. Evidence 
gap maps are evidence collections that map out existing 
and ongoing systematic reviews or primary studies in a 
sector or subsector, such as maternal health, HIV/AIDS 
and agriculture. They present a visual overview of existing 
evidence and therefore highlight the areas of gaps within 
the evidence landscape.36
ConClusIons
It is important that HTA and guideline organisations use 
their systematic processes to identify research gaps and 
then subsequently link with national research funders to 
ensure they are addressed. NICE therefore supports the 
reducing research waste campaign by ensuring that the 
research it recommends has a beneficial impact on the 
health and care of the people, as it has been systematically 
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identified as a genuine gap in the health evidence or a 
method that needs further clarification or development.
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